Yimei Shan1,2, Yinghong Kong3, Yan Zhou1, Jingjing Guo1, Qiyun Shi1, Sicheng Li1, Heming Guo1, Yiting Huang4, Sisi Ding5, Cuiping Liu5, Lei Cao5, Yun Huang1, Chen Fang6,7, Ji Hu8. 1. Department of Endocrinology, The Second Affiliated Hospital of Soochow University, Suzhou, China. 2. Clinical Medicine Research Center, Affiliated Hospital 2 of Nantong University, Nantong, China. 3. Department of Endocrinology, Changshu No. 2 People's Hospital, Changshu, China. 4. Department of Clinical Nutrition, The Second Affiliated Hospital of Soochow University, Suzhou, China. 5. Jiangsu Key Laboratory of Clinical Immunology, Soochow University, Suzhou, China. 6. Department of Endocrinology, The Second Affiliated Hospital of Soochow University, Suzhou, China. afa9911@sina.com. 7. Department of Clinical Nutrition, The Second Affiliated Hospital of Soochow University, Suzhou, China. afa9911@sina.com. 8. Department of Endocrinology, The Second Affiliated Hospital of Soochow University, Suzhou, China. huji@suda.edu.cn.
Abstract
AIMS: Chronic inflammation of autoimmune diseases, including type 1 diabetes (T1D), is mainly mediated by memory T(Tm) cells, predominantly effector memory T (Tem) cells. The roles of the programmed death-1 (PD-1) receptor on lymphocytes have been well studied in tumor and other infection models. However, little is known about the relationship between the expression of PD-1 on CD8+ Tem cells and the pathogenesis of T1D. METHODS: A total of 52 patients diagnosed with T1D and 39 gender-, age-, and ethnically matched health control individuals were enrolled in this study. Peripheral blood mononuclear cells from these individuals were isolated and analyzed by flow cytometry. We evaluated the frequencies of PD-1+ CD8+ memory T cell subsets from patients' peripheral blood with T1D and the spleen cells of nonobese diabetic (NOD) mice in the present study. We also investigated the effects of blocking PD-1/PD-L1 pathway on islet's inflammation in NOD mice. RESULTS: Frequencies of PD-1+ CD8+ Tem cells were decreased significantly in PBMC of patients with T1D (40.73 ± 12.72 vs 47.43 ± 15.56, *p < 0.05). The frequencies of PD-1+ CD8+ Tem cells were decreased in patients with T1D who were positive for two or more autoantibodies compared with the patients with one autoantibody (13.46% vs 46.95 ± 12.72%, *p < 0.05). Meanwhile, the frequencies of PD-1+ CD8+ central memory T (Tcm) cells were also significantly decreased in patients with two or more autoantibodies compared with other groups (≥ 2AAb vs HC 33.1 ± 8.92% vs 43.71 ± 11.78%, *p < 0.05; ≥ 2AAb vs AAb-33.1 ± 8.92% vs 41.65 ± 11.2%, *p < 0.05; ≥ 2AAb vs 1AAb 33.1 ± 8.92% vs 48.09 ± 10.58%, ***p < 0.001). The frequencies of PD-1+CD8+ Tem cells were positively correlated with fasting serum C-peptide levels (r = 0.4308, *p < 0.05) and C-peptide levels 2 h after meal in T1D patients (r = 0.5723, **p < 0.01). The frequencies of PD-1+CD8+ Tcm cells were only negatively correlated with the levels of HbA1c (r = - 0.2992, *p < 0.05). Similarly, the frequencies of PD-1+CD8+ Tem were significantly decreased in intervention group (anti-mouse PD-1 mAb) compared with the control group (14.22 ± 6.455% vs 27.69 ± 9.837%, *p < 0.05). Pathologically, CD8, PD-1 and PD-L1 were strongly expressed in the islets of diabetic mice after PD-1 blockade. CONCLUSIONS: It is the first report of the expression of PD-1 on CD8+ Tem cells in T1D in the present study. Our observations suggest that the PD-1/PD-L1 signal pathway on CD8+ Tem cells of T1D subjects might identify a new pathway for delaying the occurrence and development by inhibiting autoimmunity.
AIMS: Chronic inflammation of autoimmune diseases, including type 1 diabetes (T1D), is mainly mediated by memory T(Tm) cells, predominantly effector memory T (Tem) cells. The roles of the programmed death-1 (PD-1) receptor on lymphocytes have been well studied in tumor and other infection models. However, little is known about the relationship between the expression of PD-1 on CD8+ Tem cells and the pathogenesis of T1D. METHODS: A total of 52 patients diagnosed with T1D and 39 gender-, age-, and ethnically matched health control individuals were enrolled in this study. Peripheral blood mononuclear cells from these individuals were isolated and analyzed by flow cytometry. We evaluated the frequencies of PD-1+ CD8+ memory T cell subsets from patients' peripheral blood with T1D and the spleen cells of nonobese diabetic (NOD) mice in the present study. We also investigated the effects of blocking PD-1/PD-L1 pathway on islet's inflammation in NOD mice. RESULTS: Frequencies of PD-1+ CD8+ Tem cells were decreased significantly in PBMC of patients with T1D (40.73 ± 12.72 vs 47.43 ± 15.56, *p < 0.05). The frequencies of PD-1+ CD8+ Tem cells were decreased in patients with T1D who were positive for two or more autoantibodies compared with the patients with one autoantibody (13.46% vs 46.95 ± 12.72%, *p < 0.05). Meanwhile, the frequencies of PD-1+ CD8+ central memory T (Tcm) cells were also significantly decreased in patients with two or more autoantibodies compared with other groups (≥ 2AAb vs HC 33.1 ± 8.92% vs 43.71 ± 11.78%, *p < 0.05; ≥ 2AAb vs AAb-33.1 ± 8.92% vs 41.65 ± 11.2%, *p < 0.05; ≥ 2AAb vs 1AAb 33.1 ± 8.92% vs 48.09 ± 10.58%, ***p < 0.001). The frequencies of PD-1+CD8+ Tem cells were positively correlated with fasting serum C-peptide levels (r = 0.4308, *p < 0.05) and C-peptide levels 2 h after meal in T1D patients (r = 0.5723, **p < 0.01). The frequencies of PD-1+CD8+ Tcm cells were only negatively correlated with the levels of HbA1c (r = - 0.2992, *p < 0.05). Similarly, the frequencies of PD-1+CD8+ Tem were significantly decreased in intervention group (anti-mouse PD-1 mAb) compared with the control group (14.22 ± 6.455% vs 27.69 ± 9.837%, *p < 0.05). Pathologically, CD8, PD-1 and PD-L1 were strongly expressed in the islets of diabeticmice after PD-1 blockade. CONCLUSIONS: It is the first report of the expression of PD-1 on CD8+ Tem cells in T1D in the present study. Our observations suggest that the PD-1/PD-L1 signal pathway on CD8+ Tem cells of T1D subjects might identify a new pathway for delaying the occurrence and development by inhibiting autoimmunity.
Authors: Slobodan Culina; Ana Ines Lalanne; Georgia Afonso; Karen Cerosaletti; Sheena Pinto; Guido Sebastiani; Klaudia Kuranda; Laura Nigi; Anne Eugster; Thomas Østerbye; Alicia Maugein; James E McLaren; Kristin Ladell; Etienne Larger; Jean-Paul Beressi; Anna Lissina; Victor Appay; Howard W Davidson; Søren Buus; David A Price; Matthias Kuhn; Ezio Bonifacio; Manuela Battaglia; Sophie Caillat-Zucman; Francesco Dotta; Raphael Scharfmann; Bruno Kyewski; Roberto Mallone Journal: Sci Immunol Date: 2018-02-02
Authors: Ania Skowera; Kristin Ladell; David A Price; Mark Peakman; James E McLaren; Garry Dolton; Katherine K Matthews; Emma Gostick; Deborah Kronenberg-Versteeg; Martin Eichmann; Robin R Knight; Susanne Heck; Jake Powrie; Polly J Bingley; Colin M Dayan; John J Miles; Andrew K Sewell Journal: Diabetes Date: 2014-09-23 Impact factor: 9.461
Authors: Luca Gattinoni; Enrico Lugli; Yun Ji; Zoltan Pos; Chrystal M Paulos; Máire F Quigley; Jorge R Almeida; Emma Gostick; Zhiya Yu; Carmine Carpenito; Ena Wang; Daniel C Douek; David A Price; Carl H June; Francesco M Marincola; Mario Roederer; Nicholas P Restifo Journal: Nat Med Date: 2011-09-18 Impact factor: 53.440
Authors: Rama S Akondy; Mark Fitch; Srilatha Edupuganti; Shu Yang; Haydn T Kissick; Kelvin W Li; Ben A Youngblood; Hossam A Abdelsamed; Donald J McGuire; Kristen W Cohen; Gabriela Alexe; Shashi Nagar; Megan M McCausland; Satish Gupta; Pramila Tata; W Nicholas Haining; M Juliana McElrath; David Zhang; Bin Hu; William J Greenleaf; Jorg J Goronzy; Mark J Mulligan; Marc Hellerstein; Rafi Ahmed Journal: Nature Date: 2017-12-13 Impact factor: 69.504
Authors: Ben Youngblood; J Scott Hale; Haydn T Kissick; Eunseon Ahn; Xiaojin Xu; Andreas Wieland; Koichi Araki; Erin E West; Hazem E Ghoneim; Yiping Fan; Pranay Dogra; Carl W Davis; Bogumila T Konieczny; Rustom Antia; Xiaodong Cheng; Rafi Ahmed Journal: Nature Date: 2017-12-13 Impact factor: 49.962